Ji Guang WangYook Chin ChiaChen Huan ChenSungha ParkSatoshi HoshideNaoko TomitaniTomoyuki KabutoyaJinho ShinYuda TuranaArieska Ann SoenartaJam Chin TayPeera BuranakitjaroenJennifer NailesHuynh Van MinhSaulat SiddiqueJorge SisonGuru Prasad SogunuruApichard SukonthasarnBoon Wee TeoNarsingh VermaYu Qing ZhangTzung Dau WangKazuomi KarioUniversity Medicine and Pharmacy, Hue UniversityDe La Salle Health Sciences InstituteSunway UniversityHanyang University Medical CenterJichi Medical UniversityYonsei University Health SystemShanghai Jiao Tong University School of MedicineMadras Institute of Orthopaedics and Traumatology HospitalsKathmandu UniversityUniversity of the East Ramon Magsaysay Memorial Medical CenterFatima Memorial HospitalUniversitas Katolik Indonesia Atma JayaUniversitas IndonesiaUniversity of MalayaFuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical CollegeYong Loo Lin School of MedicineNational Taiwan University College of MedicineKing George's Medical UniversityFaculty of Medicine, Siriraj Hospital, Mahidol UniversityNational Yang-Ming University, School of MedicineTan Tock Seng HospitalChiang Mai University2020-03-262020-03-262020-01-01Journal of Clinical Hypertension. (2020)17517176152461752-s2.0-85078722210https://repository.li.mahidol.ac.th/handle/20.500.14594/53887© 2020 Wiley Periodicals, Inc. The new Chinese hypertension guideline comprehensively covers almost all major aspects in the management of hypertension. In this new guideline, hypertension remains defined as a systolic/diastolic blood pressure of at least 140/90 mm Hg. For risk assessment, a qualitative approach is used similarly as in previous Chinese guidelines according to the blood pressure level and the presence or absence of other risk factors, target organ damage, cardiovascular complications, and comorbid diseases. The therapeutic target is 140/90 mm Hg in general, and if tolerated, especially in high-risk patients, can be more stringent, that is, 130/80 mm Hg. However, a less stringent target, that is, 150/90 mm Hg, is used in the younger (65-79 years, if tolerated, 140/90 mm Hg) and older elderly (≥80 years). Five classes of antihypertensive drugs, including β-blockers, can be used either in initial monotherapy or combination. The guideline also provided information on the management of hypertension in several special groups of patients and in the presence of secondary causes of hypertension. To implement the guideline recommendations, several nationwide hypertension control initiatives are being undertaken with new technology. The new technological platforms hopefully will help improve the management of hypertension and generate scientific evidence for future hypertension guidelines, including a possible Asian hypertension guideline in the near future.Mahidol UniversityMedicineArticleSCOPUS10.1111/jch.13803